Document is current
Any future updates will be listed below
-
Authors
Chen, Zekai
Triatin, Rima D.
Luo, Li
Snieder, Harold
Schmidt, A. Floriaan
Ditmarsch, Marc
Kastelein, John J. P.
Dullaart, Robin P. F.
Kuivenhoven, Jan Albert
Thio, Chris H. L.
-
Funding
Funding for this research was provided by:
NewAmsterdam Pharma (112346)
- License Information
-
More Information
Article History
Received: 19 December 2025
Accepted: 29 April 2026
First Online: 14 May 2026
Declarations
:
: UK Biobank received ethical approval from the National Information Governance Board for Health and Social Care and the National Health Service North West Centre for Research Ethics Committee (Ref: 21/NW/0157). All participants provided informed consent at recruitment to the study for their data to be used for health-related research that was in the public interest. The Lifelines protocol was approved by the UMCG Medical ethical committee under number 2007/152. All participants signed an informed consent form. This study also used aggregated GWAS data, the underlying cohorts of which received ethical approval. We refer to the original GWAS for details (Table ).
: The work was carried out with unrestricted funding from NewAmsterdam Pharma, who are developing Obicetrapib, a CETP inhibiting agent. MD, JJPK are employed by New Amsterdam Pharma, as chief development officer, and chief scientific officer, respectively.
